90407c8f-6193-45c7-9f29-0783aeeab94d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.290
- UV_RESPONSE_DN+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- HEDGEHOG_SIGNALING+0.210
- KRAS_SIGNALING_UP+0.170
- KRAS_SIGNALING_DN+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
- ESTROGEN_RESPONSE_EARLY+0.140
- APICAL_JUNCTION+0.130
- MITOTIC_SPINDLE+0.110
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.580
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.550
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.420
- DNA_REPAIR-0.360
- E2F_TARGETS-0.360
- MYC_TARGETS_V1-0.350
- FATTY_ACID_METABOLISM-0.310
- GLYCOLYSIS-0.290
- XENOBIOTIC_METABOLISM-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.866 |
| 2 | c848ccf8-14d9-4fbd-8366-d4e4ab4dc2e5 | — | — | 0.860 |
| 3 | TCGA-D8-A1XB-01A-11R-A14D-07 | — | A | 0.852 |
| 4 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.845 |
| 5 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.838 |
| 6 | SRR29022838 | — | A | 0.820 |
| 7 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.817 |
| 8 | X8de42096.ef3e.4864.8ee1.2ee7672c1c82 | — | cohortSQ1 | 0.814 |
| 9 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.813 |
| 10 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |